Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Jeffrey S. Stonebraker"'
Autor:
Jeffrey S. Stonebraker
Publikováno v:
INFORMS Transactions on Education. 23:154-158
The interactive case study requires student teams to engage with the instructor using a structured decision analysis process in deciding whether to develop a new drug to treat blood clots in legs. There is role-playing in the interactive case study w
Autor:
Jeffrey S. Stonebraker
Publikováno v:
INFORMS Transactions on Education. 23:159-163
History: This paper has been accepted for the INFORMS Transactions on Education Special Section on Cases Based on Real-World Projects from the INFORMS Journal on Applied Analytics.
Autor:
Jeffrey S. Stonebraker, Mark Crowther, Randall Curtis, Declan Noone, Michael B. Nichol, Federico Germini, Brian O'Mahony, Mark W. Skinner, Drashti Pete, David Page, Chatree Chai-Adisaksopha, Neil Frick, Lehana Thabane, Alfonso Iorio
Publikováno v:
Haemophilia. 27:993-1001
Background Knowledge about sexual health, difficulty with sexual activity and intimacy (sexual difficulty), in people with hemophilia is little understood. Objectives The objectives were to determine the prevalence of sexual difficulty in people livi
Autor:
Antonio Suarez, Sudipta Dasmohapatra, Jeffrey S. Stonebraker, Camilla Abbati de Assis, Ronalds Gonzalez, Carlos Carrillo, Hasan Jameel, Jeffrey P. Prestemon
Publikováno v:
BioResources. 16:19-45
This study aims to examine how organizations in the bio-based industry perceive risks and perform risk analysis within the capital investment decision-making process. More specifically, this study aims to assess sources of uncertainty commonly consid
Autor:
Ellia Tootoonchian, Glenn F. Pierce, Brian O'Mahony, Michael Makris, Bruce L. Evatt, Alfonso Iorio, M. Brooker, Mark W. Skinner, Paula H B Bolton-Maggs, Donna Coffin, Jeffrey S. Stonebraker
Publikováno v:
Haemophilia. 26:591-600
Introduction The World Federation of Hemophilia (WFH) strives to achieve care for all patients with inherited bleeding disorders through research, advocacy, capacity building and education. The WFH developed and implemented the Annual Global Survey (
Publikováno v:
Haemophilia. 27
Introduction The World Federation of Hemophilia started measuring factor utilization at the country level as IU/capita (International Units of factor concentrates used per country population) in 2001 for its Annual Global Survey. IU/capita have been
Autor:
Jeffrey S. Stonebraker, David Page, Mark Crowther, Mark W. Skinner, Alfonso Iorio, Brian O'Mahony, Lehana Thabane, Chatree Chai-Adisaksopha, Declan Noone, Michael B. Nichol, Randall Curtis, Neil Frick
Publikováno v:
Haemophilia. 25:75-83
Background The Patient Reported Outcomes, Burdens and Experiences (PROBE) study aims to develop and validate questionnaire for assessing health status in patients with haemophilia and participants without bleeding disorders. Objective To investigate
Autor:
Federico, Germini, Victoria, Borg Debono, David, Page, Victoria, Zuk, Alexandra, Kucher, Chris, Cotoi, Nicholas, Hobson, Michael, Sevestre, Mark W, Skinner, Alfonso, Iorio, Jeffrey S, Stonebraker
Publikováno v:
JMIR human factors. 9(1)
Background The Patient-Reported Outcomes, Burdens, and Experiences (PROBE) questionnaire is a tool for assessing the quality of life and disease burden in people living with hemophilia. Objective The objectives of our study were (1) to assess the nee
Autor:
Randall Curtis, Neil Frick, Declan Noone, Michael B. Nichol, David Page, Federico Germini, Alfonso Iorio, Mark W. Skinner, Jeffrey S. Stonebraker, Brian O'Mahony, Chatree Chai-Adisaksopha
Publikováno v:
Haemophilia : the official journal of the World Federation of HemophiliaREFERENCES. 27
Introduction There are limited data on the impact of haemophilia on health status and health-related quality of life (HRQL) in people with non-severe (mild and moderate) haemophilia. Aim To evaluate the health status of people living with mild or mod
Publikováno v:
Haemophilia : the official journal of the World Federation of HemophiliaREFERENCES. 27(1)
Introduction Increased usage of emicizumab in the United States will affect standard half-life (SHL) and extended half-life (EHL) products usage and cost. Aim To model the usage and cost of SHL and EHL products, and emicizumab to treat haemophilia A